Clinical intervention effect of TACE combined with 3DCRT in patients with primary liver cancer.
3DCRT
TACE
clinical intervention
effect
influence
primary liver cancer
Journal
American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
01
2021
accepted:
19
03
2021
entrez:
11
8
2021
pubmed:
12
8
2021
medline:
12
8
2021
Statut:
epublish
Résumé
To investigate the clinical intervention effect of transcatheter arterial chemoembolization (TACE) combined with three-dimensional conformal radiotherapy (3DCRT) in patients with primary liver cancer (PLC). A total of 110 PLC patients admitted to our hospital were selected and divided into the study group (SG, n=60, treated with TACE combined with 3DCRT) and the control group (CG, n=50, treated with TACE alone) in accordance with the different clinical intervention measures. The clinical intervention effect and the changes of tumor factors and quality of life scores were compared between the two groups before and after intervention, and the three-year survival and the incidence of adverse reactions were evaluated. The objective response rate (ORR) and disease control rate (DCR) in the SG (78.33% and 95.00%) were higher than those in the CG (38.00% and 80.00%), whereas the carcinoembryonic antigen (CEA) and alpha fetoprotein (AFP) levels in the SG were lower than those in the CG ( TACE combined with 3DCRT has a high safety and leads to remarkable clinical intervention effects, marked improvement of the serological indices, better quality of life, as well as satisfactory long-term survival.
Types de publication
Journal Article
Langues
eng
Pagination
7960-7967Informations de copyright
AJTR Copyright © 2021.
Déclaration de conflit d'intérêts
None.
Références
Cancer Control. 2018 Jan-Mar;25(1):1073274817744621
pubmed: 29327594
J Cancer Res Ther. 2018 Jan;14(1):163-170
pubmed: 29516981
J Cancer. 2016 Jul 04;7(11):1413-20
pubmed: 27471557
Zhonghua Yu Fang Yi Xue Za Zhi. 2018 Apr 6;52(4):402-408
pubmed: 29614608
J Health Soc Behav. 2019 Jun;60(2):204-221
pubmed: 31122076
Int J Cancer. 2018 Oct 15;143(8):1896-1903
pubmed: 29756347
Br J Nurs. 2018 Feb 1;27(Sup4b):S1-S8
pubmed: 29461871
Cell Death Dis. 2018 Mar 14;9(3):398
pubmed: 29540666
Theranostics. 2018 Feb 12;8(6):1740-1751
pubmed: 29556353
Neoplasia. 2018 Jan;20(1):57-68
pubmed: 29195126
Pers Relatsh. 2018 Mar;25(1):87-102
pubmed: 30166932
Int J Prison Health. 2018 Mar 12;14(1):34-45
pubmed: 29480768
J Cancer. 2018 Aug 6;9(17):3187-3195
pubmed: 30210642
Medicine (Baltimore). 2018 Apr;97(17):e0528
pubmed: 29703025
Cancer Control. 2018 Jan-Mar;25(1):1073274817744658
pubmed: 29353494
Surg Endosc. 2018 Jan;32(1):46-52
pubmed: 28639044
PLoS One. 2018 Jun 22;13(6):e0199532
pubmed: 29933395
Eur J Cancer. 2017 Sep;83:56-70
pubmed: 28715695
Cancer Cell. 2018 Jun 11;33(6):1061-1077.e6
pubmed: 29894692